Navigation Links
Cadus Reports 2008 Results
Date:3/31/2009

NEW YORK, March 31 /PRNewswire-FirstCall/ -- Cadus Corporation (OTC Bulletin Board: KDUS) announced today financial results for the full year ended December 31, 2008.

Revenues for the full year 2008 were $100,000, compared to $100,000 for the full year 2007. Net loss for the full year 2008 was $1,268,898, compared to net loss of $272,110 for the full year 2007. Basic and diluted net loss per share for the full year 2008 was $0.10, compared to basic and diluted net loss per share for the full year 2007 of $0.02. The increase in net loss and basic and diluted net loss per share for the full year 2008 was attributable to a decrease in interest income of $597,613, an increase in loss on redemption and reduction to net asset value of short-term investments of $408,453, a reduction of income in other ventures of $6,435 offset by a decrease in provision for franchise and income taxes of $15,519 and a decrease in general and administrative expenses of $194.

As of December 31, 2008, Cadus had 13,144,040 shares outstanding.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2008. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of patent protection and the risk of obsolescence of the company's technologies.

(Tables Follow)

    Cadus Corporation and Subsidiary
    Consolidated Balance Sheets

                                         ASSETS
                                         ------

                                            December 31,     December 31,
                                               2008             2007

    Current assets:
        Cash and cash equivalents            $19,236,212     $2,444,376
        Short term investments                 5,048,775     22,960,545
        Interest receivable                       13,116        102,518
        Prepaid and other current assets          14,090          1,150

            Total current assets              24,312,193     25,508,589

    Investment in other ventures                 193,718        186,790
    Patents, net                                 464,401        550,834
            Total assets                     $24,970,312    $26,246,213


                                 LIABILITIES AND STOCKHOLDERS' EQUITY
                                 ------------------------------------
    Current liabilities:
        Accrued expenses and other
         current liabilities                     $15,055        $22,352

            Total current liabilities             15,055         22,352

    Commitments and contingencies

    Stockholders' equity:
        Common stock                             132,857        132,857
        Additional paid-in capital            59,847,443     59,847,149
        Accumulated deficit                  (34,724,968)   (33,456,070)
        Treasury stock, at cost                 (300,075)      (300,075)
               Total stockholders' equity     26,955,257     26,223,861
               Total liabilities and
                stockholders' equity         $24,970,312    $26,246,213


    Cadus Corporation and Subsidiary
    Condensed Consolidated Statements of Operations

                                            For the Years Ended December 31,
                                                    2008            2007

    License and maintenance fees                $100,000        $100,000
            Total revenues                       100,000         100,000
    Costs and expenses:
        General and administrative               557,744         557,938
        Amortization of patent costs              86,433          86,433
        Income from equity in other ventures     (6,928)        (13,363)
            Total costs and expenses             637,249         631,008
    Operating (loss)                           (537,249)       (531,008)

    Other income (expense):
        Interest income                          714,670       1,312,283
        Loss on sale and redemption of
         marketable securities                 (222,305)       (668,246)
        Investment reduction to net asset
         value                               (1,174,756)       (320,362)
            Total other income (expense)       (682,391)        323,675
    (Loss) before income tax provision       (1,219,640)       (207,333)

    Provision for franchise and income
     taxes                                       49,258          64,777
            Net (loss)                      ($1,268,898)      ($272,110)
    Basic and diluted net (loss) per
     share                                       ($0.10)         ($0.02)
    Weighted average shares of common
     stock outstanding - basic and
     diluted                                 13,144,040      13,144,040


'/>"/>
SOURCE Cadus Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: